NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
PARAGON Study Confirms Sustained Efficacy and Safety of NEUROMARK® System in Allergic and Nonallergic Rhinitis Patients GALWAY, Ireland,…
Lilly’s Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer’s disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with…
Sleep Aids Market to Hit US$ 118.97 Billion by 2033, Growing at 7.8% CAGR
AUSTIN, Texas and TOKYO, Sept. 19, 2025 /PRNewswire/ — According to DataM Intelligence, the global sleep aids market…
In Vitro Diagnostics (IVD) Quality Control Market worth $2.15 billion by 2030 with 5.5% CAGR
DELRAY BEACH, Fla., Sept. 19, 2025 /PRNewswire/ — The global In Vitro Diagnostics Quality Control Market, valued at…
AAOS Updates Clinical Practice Guideline for the Management of Rotator Cuff Injuries
Updated guideline based on the latest evidence-based recommendations ROSEMONT, Ill., Aug. 28, 2025 /PRNewswire/ — The American Academy…
Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Leal Therapeutics is developing first-in-class therapeutics to correct metabolic imbalances in the brain for treatment of high unmet…
Ultima Genomics and Gene by Gene Partner to Expand Global Access to High-Quality, Low-Cost Sequencing on the UG 100™ Platform
Collaboration Extends Global Reach of High-Performance Genomic Sequencing on the UG 100™ Platform FREMONT, Calif. and HOUSTON, Aug.…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb’s Izalontamab brengitecan (Iza-bren) based on data…